Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson's Legal Challenges Mount

share with twitter share with LinkedIn share with facebook
share via e-mail
10/14/2019 | 08:30am EST

By Peter Loftus

Johnson & Johnson, facing lawsuits from more than 100,000 plaintiffs over its product safety and marketing tactics, has taken the aggressive strategy of battling many of the cases in court.

And it is losing. A lot.

Juries and judges have ordered the health-products giant to pay billions of dollars in several recent trials over claims that J&J's signature baby powder and certain drugs and medical devices injured people, and that its marketing practices fueled the opioid-addiction epidemic.

The latest: A Philadelphia jury last week awarded $8 billion in punitive damages to a man claiming his use of J&J's antipsychotic Risperdal when he was a boy caused abnormal breast enlargement. J&J says it properly disclosed the drug's risks and benefits, and plans to appeal the verdict.

In August, an Oklahoma judge ordered J&J to pay $572 million to the state for contributing to the opioid-addiction crisis, a judgment the company is appealing. Last year, a St. Louis jury found that J&J should pay $4.7 billion to 22 women and their families who alleged the company's baby powder caused ovarian cancer. J&J, which says the talcum powder is safe and doesn't cause cancer, is appealing the decision.

The New Brunswick, N.J., company faced lawsuits from at least 103,300 people or entities in U.S. courts at the middle of this year, up from the 8,580 plaintiffs pending in October 2011, according to a Wall Street Journal review of J&J's securities filings. J&J discloses the number of plaintiffs for the most significant of its product-liability cases in its filings.

The number of talc lawsuit plaintiffs surged to 15,500 as of June 30, from 1,400 in early 2016, the Journal analysis found. Plaintiffs in personal-injury lawsuits over J&J's pelvic mesh devices for women have declined from a peak of more than 55,000 pending in 2017 but still number about 24,800.

J&J is challenging many of the lawsuits, rather than quickly settling, according to lawyers on both sides. "Their natural reflex is to fight and delay, drag it out as long as they can," said Andy Birchfield, an attorney with Beasley Allen in Montgomery, Ala., who has sued J&J over baby powder and other products.

The Risperdal damages and some other awards are likely to be reduced by judges, and possibly overturned, on appeal. Yet the losses signal J&J may ultimately have to pay a costly sum to resolve the lawsuits. The opioid litigation alone could cost J&J $5 billion to $10 billion to settle, Wells Fargo analysts have estimated.

J&J has won its share of trials. The company argues science supports the safety of its products, and that its increasing caseload is a product of aggressive plaintiff's lawyers eyeing the company's big pockets. It is in the company's best interest, its outside lawyers say, to deter more lawsuits lacking merit by avoiding premature settlements now.

J&J is approaching the litigation "with an eye to managing this onslaught overall, and not creating false incentives for lawyers to file even more claims that are marginal at best," said John Beisner, a partner with Skadden, Arps, Slate, Meagher & Flom LLP who is defending J&J in litigation over talc and some other products.

J&J may be following in the footsteps of Merck & Co., which took to trial a number of lawsuits alleging its Vioxx painkiller caused heart attacks and strokes, said Nora Freeman Engstrom, a law professor at Stanford Law School who studies personal-injury litigation.

Merck won more verdicts than it lost, and ultimately agreed in 2007 to settle nearly all of the lawsuits for $4.85 billion, lower than analysts initially expected. Yet a key difference, Ms. Engstrom said, is that J&J is battling litigation on a large scale for multiple products.

Concerns about J&J's litigation risk have weighed on its stock, which is down about 12% since its 52-week high in December. Some analysts say the slide reflects investors' expectations that J&J may have to spend from $20 billion to $50 billion to resolve all of the litigation. J&J had $81.6 billion in revenue last year.

In August, Moody's Investors Service changed its outlook for J&J's bond rating to negative from stable, citing uncertainty over the outcome of litigation.

Eye-catching verdicts also are hurting the company's reputation for trustworthiness, amassed from decades of careful marketing to parents and its famous handling of a Tylenol scare. Recent legal losses have dropped J&J to 57th out of 58 companies in a pharmaceutical reputation index developed by Alva Group, which bases its scores on mentions in the news, social media and analyst reports. J&J was in the index's top 10 in 2014.

A J&J spokesman said the company's reputation remains strong because it has developed high-quality consumer products and treatments for cancer and HIV. He said the company's victories at trial and reversals of losses on appeal don't garner the same level of attention as high-dollar trial losses.

The company's wins include two talc trials last week in which California juries sided with the company. And it has settled others. In March, J&J and partner Bayer AG said they agreed to pay $775 million to resolve most claims that their blood thinner Xarelto causes excessive bleeding. The companies had won several Xarelto trials and didn't admit liability in the settlement. This month, J&J agreed to pay $20.4 million to settle opioid lawsuits filed by two Ohio counties, avoiding a trial.

Some lawyers say the longer litigation continues, the easier the cases become for plaintiffs to win because more documentation is unearthed and plaintiffs' lawyers can refine their strategies based on earlier trials.

"The cases only get better for plaintiffs, not worse," said Richard Golomb, a Philadelphia attorney representing women who have sued over J&J's baby powder.

J&J, however, has a reason for holding out on a large talc settlement. It has asked a federal judge in New Jersey overseeing pretrial proceedings for a majority of the talc suits to exclude testimony from the plaintiffs' expert witnesses who claim talc causes cancer. Plaintiffs' lawyers say the testimony should be allowed.

If the judge sides with J&J, it could effectively wipe out most of the talc lawsuits; a decision is expected in the coming months.

Write to Peter Loftus at peter.loftus@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 0.09% 70.43 Delayed Quote.16.30%
JOHNSON & JOHNSON 3.04% 134.94 Delayed Quote.1.48%
MERCK AND COMPANY 0.41% 84.9 Delayed Quote.11.11%
MERCK KGAA 1.74% 108 Delayed Quote.20.03%
MERCK LTD -0.08% 4291.65 End-of-day quote.36.24%
WELLS FARGO & COMPANY 0.58% 53.8 Delayed Quote.16.08%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
05:45aJ&J Rapidly Tested Its Baby Powder After Asbestos Finding -- and the Results ..
11/16Johnson & Johnson Opioid Verdict Cut -- WSJ
11/15Johnson & Johnson's Oklahoma Opioid Penalty Reduced to $465 Million
11/15JOHNSON & JOHNSON : Oklahoma judge reduces J&J order in opioid lawsuit by $107M
11/15JOHNSON & JOHNSON : Oklahoma judge reduces amount Johnson & Johnson must pay sta..
11/13JOHNSON & JOHNSON : CARIBBEAN-POPULATION-International Population Summit opens i..
11/12JOHNSON & JOHNSON : Defendants in opioid case say politico's input not needed
11/12JOHNSON & JOHNSON : TREMFYA a First-in-Class IL-23 p19 Subunit Inhibitor, Meets ..
11/12JOHNSON & JOHNSON : Janssen Pharmaceutical - TREMFYA, a First-in-Class IL-23 p19..
11/11J&J'S JANSSEN : Tremfya Meets Main Endpoints in Psoriatic Arthritis Studies
More news
Financials (USD)
Sales 2019 82 218 M
EBIT 2019 25 649 M
Net income 2019 17 334 M
Debt 2019 6 823 M
Yield 2019 2,79%
P/E ratio 2019 20,6x
P/E ratio 2020 18,2x
EV / Sales2019 4,40x
EV / Sales2020 4,13x
Capitalization 355 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 149,37  $
Last Close Price 134,94  $
Spread / Highest target 28,2%
Spread / Average Target 10,7%
Spread / Lowest Target -4,40%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.48%355 145
ROCHE HOLDING AG20.79%255 382
MERCK AND COMPANY11.11%216 154
PFIZER-14.59%206 312
NOVARTIS18.75%202 726
NOVO NORDISK AS30.56%135 921